

Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma

Tamer Othman,¹ Paul Frankel,² Pamela Allen,³ Leslie L. Popplewell,¹ Geoffrey Shouse,¹ Tanya Siddiqi,¹ Alexey V. Danilov,¹ Nora Ruel,² Shari Daniels,¹ Lacolle Peters,¹ Stella Khoo,¹ Steven T. Rosen,¹ Elad Sharon,⁴ Miguel Villalona-Calero,⁵ Christopher Ruel,² Joseph Tuscano⁶ and Alex F. Herrera¹

¹Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA; ²Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA; ³Winship Cancer Institute at Emory University, Decatur, GA; ⁴Division of Cancer Treatment and Diagnosis, National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD; ⁵Department of Medical Oncology & Therapeutics Research, City of Hope National Cancer Center, Duarte, CA and ⁶Department of Internal Medicine, Division of Malignant Hematology, Cellular Therapy and Transplantation, University of California Davis School of Medicine, Sacramento, CA, USA

Correspondence: A.F. Herrera
aherrera@coh.org

Received: January 29, 2024.

Accepted: July 10, 2024.

Early view: July 18, 2024.

<https://doi.org/10.3324/haematol.2024.285185>

©2025 Ferrata Storti Foundation

Published under a CC BY-NC license



SUPPLEMENTARY TABLE 1. Clinical characteristics of the study patients

Characteristic	Whole cohort (n = 150)	ND cohort (n = 61)	RR cohort (n = 89)	P*	mPRS groups - whole cohort			P**
					Higher benefit (n = 83, 56%)	Intermediate benefit (n = 47, 31%)	Lower benefit (n = 20, 13%)	
Age (range) y	64 (19-86)	72 (35-86)	58 (19-74)	<.001	65 (25-83)	65 (19-81)	60 (42-86)	.745
Male sex	89 (59%)	36 (59%)	53 (59%)	.949	52 (62%)	23 (49%)	14 (70%)	.180
ELN 2022, n (%)								
favorable	31 (21%)	11 (18%)	20 (23%)	.509	22 (27%)	9 (19%)	0 (0%)	.030
intermediate	29 (19%)	8 (13%)	21 (23%)	.110	15 (18%)	14 (30%)	0 (0%)	.017
adverse	90 (60%)	42 (69%)	48 (54%)	.066	46 (55%)	24 (51%)	20 (100%)	<.001
Cytogenetics, n (%)								
normal	82 (55%)	34 (56%)	48 (54%)	.826	52 (67%)	26 (55%)	4 (20%)	.003
t(8;21) or inv(16)	9 (6%)	2 (3%)	6 (7%)	.353	5 (6%)	4 (8%)	0 (0%)	.406
Chromosome 5 or 7 or 17 abnormality	7 (5%)	3 (5%)	4 (4%)	.902	4 (5%)	2 (4%)	1 (5%)	.986
Complex karyotype	19 (13%)	10 (16%)	9 (10%)	.255	4 (5%)	0 (0%)	13 (65%)	<.001
Mutation, n (%)								
<i>NPM1</i>	34 (23%)	11 (18%)	23 (26%)	.261	17 (20%)	15 (32%)	2 (10%)	.113
<i>TET2</i>	18 (12%)	10 (16%)	8 (9%)	.170	12 (14%)	4 (9%)	2 (10%)	.579
<i>ASXL1</i>	27 (18%)	17 (28%)	10 (11%)	.009	16 (19%)	11 (23%)	0 (0%)	.066
<i>DNMT3A</i>	45 (30%)	14 (23%)	31 (35%)	.118	25 (30%)	17 (36%)	3 (15%)	.224
<i>IDH1</i>	13 (9%)	6 (10%)	7 (8%)	.673	8 (10%)	5 (11%)	0 (0%)	.328
<i>IDH2</i>	30 (20%)	10 (16%)	20 (23%)	.360	24 (29%)	6 (13%)	0 (0%)	.004
<i>RUNX1</i>	29 (19%)	15 (25%)	14 (16%)	.177	20 (24%)	8 (17%)	1 (5%)	.135
<i>TP53</i>	20 (13%)	10 (16%)	10 (11%)	.361	0 (0%)	0 (0%)	20 (100%)	NA
<i>FLT3 ITD</i>	25 (17%)	13 (21%)	12 (13%)	.206	0 (0%)	25 (53%)	0 (0%)	NA
<i>FLT3 TKD</i>	5 (3%)	3 (5%)	2 (2%)	.370	3 (4%)	1 (2%)	1 (5%)	.816
<i>CBL</i>	1 (1%)	0 (0%)	1 (1%)	.406	1 (1%)	0 (0%)	0 (0%)	.669
<i>PTPN11</i>	10 (6%)	3 (5%)	7 (8%)	.477	5 (6%)	4 (8%)	1 (5%)	.818
<i>NF1</i>	1 (1%)	0 (0%)	1 (1%)	.406	1 (1%)	0 (0%)	0 (0%)	.669
<i>STAG2</i>	11 (7%)	8 (13%)	3 (3%)	.521	8 (10%)	3 (6%)	0 (0%)	.317
<i>BCOR</i>	13 (9%)	7 (11%)	6 (7%)	.311	11 (13%)	2 (4%)	0 (0%)	.070
<i>SF3B1</i>	8 (5%)	4 (6%)	4 (4%)	.580	6 (7%)	2 (4%)	0 (0%)	.042
Secondary AML, n (%)	31 (20%)	19 (31%)	12 (13%)	.008	16 (19%)	9 (19%)	6 (30%)	.541
Partner drug, n (%)								
Azacitidine	129 (86%)	60 (98%)	70 (79%)	<.001	72 (87%)	40 (85%)	17 (90%)	.864
Decitabine	8 (6%)	1 (2%)	7 (8%)	.095	3 (4%)	3 (6%)	2 (10%)	.484
LD-ARAC	12 (8%)	0 (0%)	12 (14%)	.002	8 (9%)	4 (9%)	0 (0%)	.357
Response, n (%)								
ORR (CR or CRi)	86 (57%)	33 (54%)	53 (59%)	.507	62 (75%)	17 (36%)	7(35%)	<.001


Abbreviations: AML, acute myeloid leukemia; ND, newly diagnosed; RR, relapsed or refractory; mPRS, molecular prognostic risk signature; ELN, European LeukemiaNet; LD-ARAC, low dose cytarabine; CR, complete remission; CRi, CR with incomplete hematological recovery; ORR, overall response rate; NA, not available.

*p-value is calculated between ND cohort and RR cohort


**p-value is calculated between higher-, intermediate- and lower-benefit group

SUPPLEMENTARY FIGURE 1. Clinical outcome according to the mPRS and ELN2022 model in the entire cohort - OS according to the mPRS and ELN2022 model. (A) EFS according to the mPRS and ELN2022 model. (B) Abbreviations: OS, overall survival; EFS, event free survival; mPRS, molecular prognostic risk signature; ELN, European LeukemiaNet; HR, hazard ratio; CI, confidence interval.

A.



B.



	Median OS, months (95% CI)	HR (95% CI)	P	Median EFS, months (95% CI)	HR (95% CI)	P
mPRS						
higher benefit	30.0 (13.8-46.2)		<0.001	14.9 (10.1-19.6)		<0.001
intermediate benefit	9.5 (6.5-12.6)	1.99 (1.19-3.32)	0.008	3.0 (0.2-5.6)	2.20 (1.40-3.44)	0.001
lower benefit	5.6 (2.0-9.3)	4.69 (2.58-8.55)	<0.001	1.1 (0.4-1.9)	4.28 (2.44-7.50)	<0.001
ELN 2022						
favorable	45.6 (18.3-73.0)		0.022	45.6 (15.4-75.9)		0.020
intermediate	13.8 (8.8-18.7)	2.21 (0.99-4.95)	0.054	5.9 (0.0-14.8)	2.57 (1.26-5.26)	0.010
adverse	11.5 (9.1-13.9)	2.66 (1.33-5.32)	0.006	5.7 (1.9-9.5)	2.30 (1.23-4.30)	0.009